Investors


Anthem Biosciences Limited (“Anthem”) is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”) with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem is one of the few companies in India with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, Anthem serves across a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.

With the three pillars of innovation and technology, high quality standards, and a customer-first approach, Anthem is committed to solve problems in biology and chemistry using technology



A.   Prospectus

       a.   Prospectus


B.   Red Herring Prospectus (RHP) Documents

       a.   RHP
       b.   Abridged Prospectus
      c.    Price band advertisement
      d.    Outstanding Dues to Material Creditors
      e.    Corrigendum to the RHP
       f.   Investors AV

C.   Draft Red Herring Prospectus (DRHP) Documents

       a.   DRHP
       b.   DRHP Notice Advertisement
       c.   Outstanding Dues to Material Creditors
       d.   Investors AV

D.   Industry Report

       a.    Frost & Sullivan (F&S) Report

E.   Annual Report

       a.   Fiscal 2025 (Year ending 31-March-2025)
       b.   Fiscal 2024 (Year ending 31-March-2024)
       c.   Fiscal 2023 (Year ending 31-March-2023)
       d.   Fiscal 2022 (Year ending 31-March-2022)

F.   Anthem Biosciences Limited (Consolidated Financial Statements)

       a.   Fiscal 2025 (Year ending 31-March-2025)
       b.   Fiscal 2024 (Year ending 31-March-2024)
       c.   Fiscal 2023 (Year ending 31-March-2023)
       d.   Fiscal 2022 (Year ending 31-March-2022)

G.   Anthem Biosciences Limited (Standalone Financial Statements)

       a.   Fiscal 2025 (Year ending 31-March-2025)
       b.   Fiscal 2024 (Year ending 31-March-2024)
       c.   Fiscal 2023 (Year ending 31-March-2023)
       d.   Fiscal 2022 (Year ending 31-March-2022)

H.   NeoAnthem Lifesciences Private Limited (Standalone Financial Statements)

       a.   Fiscal 2025 (Year ending 31-March-2025)
       b.   Fiscal 2024 (Year ending 31-March-2024)
       c.   Fiscal 2023 (Year ending 31-March-2023)
       d.   Fiscal 2022 (Year ending 31-March-2022)

I.   Board of Directors and Committees of the Board

       a.   Board Composition
       b.   Composition of Board Committees
       c.   Appointment Letters (Independent Directors)

J.   Annual Return

       a.   Fiscal 2024 (Year ending 31-March-2024)
       b.   Fiscal 2023 (Year ending 31-March-2023)
       c.   Fiscal 2022 (Year ending 31-March-2022)

K.   Corporate Governance Policies

      a.  Anti-Bribery & Anti-Corruption Policy
      b.  Anti-Money Laundering (AML) Policy
      c.  Code of Conduct
      d.  Code of Conduct for Board Members & Senior Management Personnel
      e.  Code of Conduct to Regulate, Monitor and Report Trading by Employees and Other Connected Persons
      f.  Code of Practices & Procedures for Fair Disclosure of UPSI
      g.  Conflict of Interest Policy
      h.  Corporate Social Responsibility Policy
      i.  Dividend Distribution Policy
      j.  Environment, Social & Governance and Climate Change Policy
      k.  Human Rights Policy
      l.  Nomination and Remuneration Policy
      m.  Policy on Determination of Materiality for Disclosure of Events or Information
      n.  Policy on evaluation of the performance of the Board of Directors
      o.  Policy on Preservation of Documents or Archival Policy
      p.  Prevention of Sexual Harassment at Workplace (POSH) Policy
      q.  Risk Management Policy
      r.  Third Party Code
      s.  Vigil Mechanism / Whistle Blower Policy for Directors and Employees
      t.  Anthem Employee Stock Option Plan 2024
      u.  Plan for orderly succession for appointment of directors and senior management
      v.  Policy for determination of material events and information under SEBI Listing Regulations
      w.  Policy for determining material subsidiaries as per the SEBI Listing Regulations
      x.  Policy for inquiry in case for leak of UPSI
      y.  Policy on materiality of RPT and on dealing with RPT

L1.   Material Contracts

       1.   Offer Agreement dated December 31, 2024
       2.   Amendment to the Offer Agreement dated June 18, 2025
       3.   Registrar Agreement dated December 31, 2024
       4.   Share Escrow Agreement dated June 18, 2025
       5.   Cash Escrow and Sponsor Banks Agreement dated July 2, 2025
       6.   Syndicate Agreement dated July 2, 2025
       7.   Underwriting Agreement dated July 16,2025

L2.   Material Documents

       1.   Certified copies of the Memorandum and Articles of Association of our Company
       2.   Certificate of incorporation dated June 13, 2006
       3.   Fresh Certificate of incorporation dated December 10, 2024
       4.   Resolution of the Board of Directors dated October 18, 2024, authorising the Offer and other related matters
       5.   Resolution of Board of Directors dated December 31, 2024, taking on record the approval for the Offer for Sale by the Selling Shareholders
       6.   Resolution of the Board of Directors dated December 31, 2024, approving the Draft Red Herring Prospectus
       7.   Resolution of the Board of Directors dated July 8, 2025, approving this Red Herring Prospectus
       8.   Resolution of the Board of Directors dated July 16, 2025, approving the Prospectus
       9.   Consent letters from the Selling Shareholders for participation in the Offer for Sale.
       10.    Authorisation by the board of directors of Viridity Tone LLP and Portsmouth LLC dated December 27, 2024 and November 7, 2024, respectively, authorizing their participation in the Offer for Sale.
       11.   Copies of annual reports of our Company for Fiscals 2025, 2024 and 2023
       12.   Consent dated July 16, 2025, from our Statutory Auditors, namely, K.P. Rao & Co., Chartered Accountants.
       13.    Certificate dated July 08,2025 and July 16, 2025, from K.P. Rao & Co., Chartered Accountants.
       14.   The examination report dated June 18, 2025, of the Statutory Auditors.
       15.   Consent letters of the Directors, the Book Running Lead Managers, the Syndicate Member, Legal Counsel to our Company as to Indian Law, Registrar to the Offer, Bankers to the Company, Escrow Collection Bank(s), Public Offer Bank(s), Refund Bank(s), Sponsor Bank(s), Chief Financial Officer and the Company Secretary and Compliance Officer, to act in their respective capacities.
       16.   Consent dated July 8, 2025, from the Chartered Engineer, namely M/s AJVA SP Appraisal Services Private Limited.
       17.   Consent dated July 8, 2025, from the Intellectual Property Consultant, namely S Majumdar & Co.
       18.   Consent letter from Frost and Sullivan (India) Private Limited dated July 8, 2025.
       19.    Independent Market Research on the Global and Indian CRO and CDMO Market” dated June 17, 2025.
       20.   Resolution dated July 8, 2025, of the Audit Committee approving the key performance indicators.
       21.    Shareholders’ agreement dated March 1, 2021.
       22.   Share Subscription and Share Purchase Agreement dated March 1, 2021
       23.   Scheme of Amalgamation dated November 30, 2017.
       24.   Waiver cum Amendment Agreement to the Shareholders’ Agreement dated December 30, 2024.
       25.   Valuation report dated December 26, 2024, issued by M/s Chajed & Co., Chartered Accountants.
       26.   Tripartite agreement dated October 21, 2024, among our Company, NSDL and the Registrar to the Offer.
       27.   Tripartite agreement executed on December 30, 2024 among our Company, CDSL and the Registrar to the Offer.
       28.   Due diligence certificate dated December 31, 2024, addressed to SEBI from the Book Running Lead Managers.
       29.    In-principle listing approval dated February 19, 2025, issued by BSE.
       30.    In-principle listing approval dated February 19, 2025, issued by NSE.
       31.   Undertaking dated March 21, 2025, issued by our Company to SEBI.
       32.   Final observations letter dated April 3, 2025, bearing reference number SEBI/CFD/RAC-DIL1/2025/10117 issued by SEBI.

M.   Regulation 46 of SEBI (LODR) Regulations, 2015



N.   Quaterly Results : FY2026


       i.   Q1FY26

           a.   Board Meeting Intimation

          b.   IR Call Invite

          c.   Financial Results

          d.   Press Release

          e.   Investor Presentation

          f.   Postal Ballot Notice

          g.   IR Call Transcript

          h.   IR Call Audio